Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMSI8N3)

Drug Name
CI-1033 Drug Info
Synonyms
Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
156414
ChEBI ID
CHEMBL31965
CAS Number
CAS 267243-28-7
TTD Drug ID
D0YB3W

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ferroptosis 2.33 0.00e+0 36/41 (87.8%) HMOX1;FTH1;SLC3A2;...
Fructose and mannose metabolism 2.17 0.00e+0 30/33 (90.91%) AKR1B10;ALDOC;HK2;...
Lysosome 2.12 0.00e+0 115/128 (89.84%) CTSA;TPP1;PPT1;...
Amino sugar and nucleotide sugar metabolism 2.02 2.51e-3 38/48 (79.17%) GNPDA1;AMDHD2;HEXB;...
Metabolism of xenobiotics by cytochrome P450 2.01 2.01e-3 49/77 (63.64%) AKR1C1;EPHX1;ALDH3A1;...
Galactose metabolism 2.00 1.68e-3 26/31 (83.87%) AKR1B10;HK2;GLA;...
Folate biosynthesis 1.99 1.44e-3 23/26 (88.46%) AKR1C3;AKR1B10;CBR1;...
Porphyrin and chlorophyll metabolism 1.95 3.77e-3 23/43 (53.49%) HMOX1;BLVRB;GUSB;...
Pentose phosphate pathway 1.92 4.47e-3 25/30 (83.33%) ALDOC;PGD;G6PD;...
Steroid hormone biosynthesis 1.91 5.03e-3 43/61 (70.49%) AKR1C3;AKR1C1;AKR1C2;...
Glutathione metabolism 1.87 6.40e-3 43/57 (75.44%) GPX2;CHAC1;GSR;...
Pentose and glucuronate interconversions 1.86 5.86e-3 17/34 (50%) AKR1B10;GUSB;UGDH;...
Cysteine and methionine metabolism 1.85 6.96e-3 43/50 (86%) PHGDH;TST;PSAT1;...
Peroxisome 1.84 7.18e-3 72/82 (87.8%) GSTK1;IDH1;CAT;...
Glycine, serine and threonine metabolism 1.79 1.01e-2 31/40 (77.5%) PHGDH;PSAT1;CBS;...
Nitrogen metabolism 1.78 1.01e-2 16/17 (94.12%) CA2;GLUL;CA12;...
ABC transporters 1.76 1.01e-2 37/45 (82.22%) DEFB1;ABCC5;ABCG2;...
One carbon pool by folate 1.75 1.06e-2 15/20 (75%) ALDH1L1;MTHFD2;SHMT1;...
Collecting duct acid secretion 1.75 1.01e-2 22/27 (81.48%) CA2;ATP6V1A;ATP6V1C1;...
Neomycin, kanamycin and gentamicin biosynthesis 1.75 1.01e-2 5/5 (100%) HK2
Legionellosis 1.74 9.58e-3 51/57 (89.47%) HSPA2;HSPA1A;NFKBIA;...
Selenocompound metabolism 1.74 1.14e-2 11/17 (64.71%) TXNRD1;SEPHS2;CTH;...
Mineral absorption 1.73 1.14e-2 48/60 (80%) HMOX1;FTH1;SLC30A1;...
Glycolysis / Gluconeogenesis 1.72 1.30e-2 56/67 (83.58%) ALDH3A1;PCK2;ALDOC;...
Ether lipid metabolism 1.71 1.41e-2 32/49 (65.31%) PLPP3;PLA2G4A;PLPP1;...
Histidine metabolism 1.69 1.97e-2 16/22 (72.73%) ALDH3A1;HNMT;CNDP2;...
Alanine, aspartate and glutamate metabolism 1.67 2.38e-2 27/37 (72.97%) ASNS;ASS1;GLUL;...
mTOR signaling pathway 1.67 2.44e-2 114/154 (74.03%) DDIT4;SLC3A2;SLC7A5;...
Protein processing in endoplasmic reticulum 1.66 2.53e-2 127/171 (74.27%) HSPA2;HERPUD1;HSPA1A;...
Necroptosis 1.64 2.95e-2 113/159 (71.07%) SQSTM1;FTH1;CAPN1;...
Arrhythmogenic right ventricular cardiomyopathy -1.69 4.67e-2 70/77 (90.91%) SLC8A2;PKP2;ITGB8;...
Amoebiasis -1.71 4.31e-2 99/102 (97.06%) IL12A;PIK3CD;PLCB3;...
Hedgehog signaling pathway -1.74 3.85e-2 43/56 (76.79%) GLI2;IQCE;GRK3;...
Relaxin signaling pathway -1.80 2.13e-2 114/129 (88.37%) GNG12;AKT1;GNB1;...
AGE-RAGE signaling pathway in diabetic complications -1.80 2.49e-2 97/100 (97%) PLCB4;NOX1;PIK3R1;...
PI3K-Akt signaling pathway -1.81 2.98e-2 317/354 (89.55%) NR4A1;FLT3;ANGPT1;...
Hypertrophic cardiomyopathy -2.00 2.49e-3 81/90 (90%) TPM3;CACNA2D2;ITGA8;...
Dilated cardiomyopathy -2.04 0.00e+0 86/96 (89.58%) TPM3;CACNA2D2;ITGA8;...
Focal adhesion -2.12 0.00e+0 180/201 (89.55%) AKT1;LAMB2;KDR;...
ECM-receptor interaction -2.16 0.00e+0 80/88 (90.91%) COL4A4;ITGA10;COL4A2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
K-562 CVCL_0004 Homo sapiens 0.01uM - 10uM 4H, 24H
Multiple myeloma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
KMS-34 CVCL_1333 Homo sapiens 0.01uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 3H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Lymph node
Burkitt lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BJAB CVCL_5711 Homo sapiens 0.01uM - 10uM 24H
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HBL-1 CVCL_4213 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly19 CVCL_8797 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly3 CVCL_8796 Homo sapiens 0.01uM - 10uM 4H, 24H
TMD8 CVCL_A440 Homo sapiens 0.01uM - 10uM 4H, 24H
Mantle cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MINO CVCL_4965 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute B-lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NALM-6 CVCL_0092 Homo sapiens 0.01uM - 10uM 24H
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
LNCaP CVCL_0395 Homo sapiens 0.04uM - 10uM 3H, 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
SK-MEL-5 CVCL_0527 Homo sapiens 0.01uM - 10uM 24H